ECS Secures $9.9m Supply Agreement into German Medicinal Cannabis Market

ECS Botanics Holdings Ltd (ASX: ECS) (“ECS” or the “Company”) is pleased to advise that it has entered into a binding three year agreement with German company Ilios Santé GmbH (“Ilios Sante”) for the supply of medicinal cannabis products, which will generate a minimum of $ 9.9m in revenue for the Company.

• ECS Botanics executes binding agreement with Ilios Santė GmbH to supply a minimum of AUD 9.9m worth of GMP manufactured, medicinal cannabis products over 3 years
• Geíman medicinal cannabis maíket continues to gíow stíongly, with Geíman legislatoís íecently moving to legalise recreational use.

ÉCS’s Head of European Operations, Michael Clark commented:

“Securing an agreement with a long term partner in Germany was an essential building block of ECS`s EU market access strategy. Ensuring that our German partner not only had the necessary narcotic licenses but also has its own clinic network, and the ability to adapt to future changes in cannabis legislation were key elements in securing the agreement. this partnership enables ECS and Ilios Sante to grow an exciting and sustainable business together in Europe`s largest medicinal cannabis market.”

Ilios Sante is based in Frankfurt, Germany. It is a fully licensed wholesale with the authorisations and permissions to import and distribute narcotics and other pharmaceutical products. Its focus is on the procurement and distíibution of medical products containing cannabinoids as an alternative medicine. Ilios Sante is part of the Bloomwell Group, which also includes Algea Care, Germany`s leading platform for therapy with medicinal cannabis.

Under the agreement ECS will exclusively supply 4 medicinal cannabis strains to Ilios Sante with a minimum revenue of $9.9m of GMP manufactured medicinal cannabis products over the following 3 years. First supply is anticipated once product registration has been completed.

Click here for the full ASX Release

This article includes content from ECS Botanics Holdings Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.